Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05865457

Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease

Led by TRB Chemedica International SA · Updated on 2026-02-05

80

Participants Needed

5

Research Sites

87 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this interventional investigation is to compare BUFY02 with TRB02 in the treatment of patients with dry eye disease. The main questions it aims to answer are: * Is BUFY02 non-inferior to TRB02 in terms of signs of DED? * Is BUFY02 non-inferior to TRB02 in terms of symptoms of DED? Participants will be asked to: * Visit the trial site at 4 different timepoints * Use the allocated study treatment everyday until the end of the study (during 3 months) * Be examined by the investigator * Complete several questionnaires * Return unused study treatment. Researchers will compare BUFY02 to TRB02 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.

CONDITIONS

Official Title

Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • At least a 3-month documented history of bilateral dry eye syndrome needing artificial tears
  • At least one eye with Oxford score 64 4 and 64 9
  • At least one objective sign of tear deficiency in at least one eligible eye
  • Having health insurance
Not Eligible

You will not qualify if you...

  • Started wearing contact lenses within the last 2 months
  • Best-corrected visual acuity less than 1/10
  • Severe dry eye disease with severe blepharitis or seasonal allergy
  • Any ocular surface issues not related to dry eye disease
  • History of ocular trauma, infection, or inflammation unrelated to dry eye disease
  • History of ocular surgery, including laser surgery
  • Unstable glaucoma
  • Use of artificial tears with preservatives within the last 2 weeks
  • Use of systemic or local medications listed in the study
  • Known allergy to any ingredient in the study treatments
  • Pregnancy or breastfeeding
  • Participation in another clinical study within the last 90 days
  • Legally restricted autonomy, freedom of decision, and action

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Medical University Graz

Graz, Austria

Actively Recruiting

2

VIROS

Vienna, Austria

Actively Recruiting

3

CHRU Brest

Brest, France

Actively Recruiting

4

Hôpital Bicêtre

Le Kremlin-Bicêtre, France

Actively Recruiting

5

CHU Nice

Nice, France

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease | DecenTrialz